These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22946088)

  • 21. EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line.
    Nishimura Y; Takiguchi S; Ito S; Itoh K
    Int J Oncol; 2015 Apr; 46(4):1721-9. PubMed ID: 25653196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
    Shrader M; Pino MS; Lashinger L; Bar-Eli M; Adam L; Dinney CP; McConkey DJ
    Cancer Res; 2007 Feb; 67(4):1430-5. PubMed ID: 17308080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells.
    Ariyama H; Qin B; Baba E; Tanaka R; Mitsugi K; Harada M; Nakano S
    J Cell Biochem; 2006 Mar; 97(4):724-34. PubMed ID: 16229013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
    Ko JC; Ciou SC; Jhan JY; Cheng CM; Su YJ; Chuang SM; Lin ST; Chang CC; Lin YW
    Mol Cancer Res; 2009 Aug; 7(8):1378-89. PubMed ID: 19671683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
    Teraishi F; Kagawa S; Watanabe T; Tango Y; Kawashima T; Umeoka T; Nisizaki M; Tanaka N; Fujiwara T
    FEBS Lett; 2005 Aug; 579(19):4069-75. PubMed ID: 16023108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
    Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
    Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
    Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.
    Park JJ; Yi JY; Jin YB; Lee YJ; Lee JS; Lee YS; Ko YG; Lee M
    Biochem Pharmacol; 2012 Apr; 83(7):849-57. PubMed ID: 22266356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy.
    Roongta UV; Pabalan JG; Wang X; Ryseck RP; Fargnoli J; Henley BJ; Yang WP; Zhu J; Madireddi MT; Lawrence RM; Wong TW; Rupnow BA
    Mol Cancer Res; 2011 Nov; 9(11):1551-61. PubMed ID: 21954435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
    Liu H; Li L; Li XQ; Liu XJ; Zhen YS
    Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo.
    Rajput A; Koterba AP; Kreisberg JI; Foster JM; Willson JK; Brattain MG
    Cancer Res; 2007 Jan; 67(2):665-73. PubMed ID: 17234777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer.
    Zhang J; Song F; Zhao X; Jiang H; Wu X; Wang B; Zhou M; Tian M; Shi B; Wang H; Jia Y; Wang H; Pan X; Li Z
    Mol Cancer; 2017 Jul; 16(1):127. PubMed ID: 28724430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.
    Li B; Gao S; Wei F; Bellail AC; Hao C; Liu T
    Oncol Rep; 2012 Jul; 28(1):15-20. PubMed ID: 22552366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epimagnolin targeting on an active pocket of mammalian target of rapamycin suppressed cell transformation and colony growth of lung cancer cells.
    Yoo SM; Lee CJ; Kang HC; Lee HS; Lee JY; Kim KD; Kim DJ; An HJ; Cho YY
    Mol Carcinog; 2019 Jul; 58(7):1221-1233. PubMed ID: 30887599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorescence resonance energy transfer based quantitative analysis of feedforward and feedback loops in epidermal growth factor receptor signaling and the sensitivity to molecular targeting drugs.
    Fujita Y; Komatsu N; Matsuda M; Aoki K
    FEBS J; 2014 Jul; 281(14):3177-92. PubMed ID: 24848561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells.
    Reddy P; Liu L; Ren C; Lindgren P; Boman K; Shen Y; Lundin E; Ottander U; Rytinki M; Liu K
    Mol Endocrinol; 2005 Oct; 19(10):2564-78. PubMed ID: 15928314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of stearoylCoA desaturase activity blocks cell cycle progression and induces programmed cell death in lung cancer cells.
    Hess D; Chisholm JW; Igal RA
    PLoS One; 2010 Jun; 5(6):e11394. PubMed ID: 20613975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
    Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
    Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth and survival of lung cancer cells: regulation by kallikrein-related peptidase 6 via activation of proteinase-activated receptor 2 and the epidermal growth factor receptor.
    Michel N; Heuzé-Vourc'h N; Lavergne E; Parent C; Jourdan ML; Vallet A; Iochmann S; Musso O; Reverdiau P; Courty Y
    Biol Chem; 2014 Sep; 395(9):1015-25. PubMed ID: 24643912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.